Lululemon Athletica vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vancouver BC premium athletic apparel (NASDAQ: LULU) ~$10.6B FY2024 revenue (+11%); women's yoga apparel leader, China +41%, US slowdown, men's 22%+ of revenue, competing with Nike and Alo Yoga.
About
lululemon athletica inc. is a Vancouver, British Columbia-based premium athletic apparel company — publicly traded on the NASDAQ (NASDAQ: LULU) as an S&P 500 Consumer Discretionary component — designing, making, and distributing technical athletic apparel (yoga, run, train, swim, golf) and lifestyle products for women (primary market), men (growing), and youth through 700+ company-owned retail stores and e-commerce at lululemon.com through approximately 36,000 employees. In fiscal year 2024 (ending February 2025), lululemon reported revenues of approximately $10.6 billion (+11% year-over-year), continuing its decade-long consistent double-digit revenue growth as the brand expanded internationally (China mainland growing 41% in FY2024, Rest of World growing 28%) while US growth slowed to low single digits as the premium yoga-adjacent apparel market reached maturation levels in core US metro markets. CEO Calvin McDonald's strategy has focused on building the international business (China, Europe, rest of world) to replicate the North American penetration that drove lululemon's exceptional 2014-2023 growth, while managing the Mirror connected fitness acquisition write-off ($500 million full goodwill impairment of the Mirror home fitness acquisition completed in June 2020 for $500 million — mirror business essentially wound down by 2023) and navigating US market saturation challenges that required product innovation investment to sustain domestic revenue growth. lululemon's core women's leggings business (Align, Wunder Under, Fast and Free pants — $100-148 price point, premium Luon and Everlux fabric technology) anchors the brand's category authority in performance athletic bottoms.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.